PULM · NASDAQ
Pulmatrix, Inc.
$1.42 +0.02 (+1.43%)
Company overview
Pulmatrix, Inc. is a clinical-stage biotechnology company that discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It is developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor in Phase 1b clinical trials for patients with stable moderate-to-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $5.2M
- Employees
- 2
- Headquarters
- Lexington, MA
- Website
- pulmatrix.com
- CEO
- Peter Ludlum
- Listed
- March 21, 2014
- P/E
- -1.15
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$14,000
- Operating income
- -$4.6M
- EBITDA
- -$4.6M
- Net income
- -$4.5M
- EPS
- -$1.23
- Total assets
- $4.5M
- Total debt
- $0.00
- Earnings yield
- -86.62%
No geographic segmentation.
Showing FY 2020
PULM
1D
NASDAQ
O1.46H1.46L1.31C1.40-0.10 (-6.67%)Vol1.83K